Literature DB >> 10680592

Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis.

S Chen1, S M Akbar, K Tanimoto, T Ninomiya, H Iuchi, K Michitaka, N Horiike, M Onji.   

Abstract

Mature and activated dendritic cells (CD83-positive DCs) are essential for the recruitment and survival of activated tumor-specific lymphocytes during carcinogenesis. The frequencies of CD83 positive DCs were almost same in peripheral blood from patients with hepatocellular carcinoma (HCC) and cirrhosis of liver (LC). However, the numbers of CD83 positive DCs in liver tissues were significant lower in HCC compared with LC (6.6+/-10.9 vs. 33.3+/-24 DCs/specimen, P<0.05). Most importantly, there were no CD83-positive DCs at cancer nodules in HCC. A role of infiltration of activated DCs in liver during hepatocarcinogenesis is shown.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10680592     DOI: 10.1016/s0304-3835(99)00312-2

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  18 in total

Review 1.  Dendritic cells and immune regulation in the liver.

Authors:  A H Lau; A W Thomson
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

2.  Study on immune function of dendritic cells in patients with esophageal carcinoma.

Authors:  Shen-Ren Chen; Yi-Ping Luo; Jin-Kun Zhang; Wei Yang; Zhi-Chao Zhen; Lin-Xin Chen; Wei Zhang
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

Review 3.  Antigen-presenting cell function in the tolerogenic liver environment.

Authors:  Angus W Thomson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-11       Impact factor: 53.106

4.  Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety.

Authors:  Y Nakamoto; E Mizukoshi; H Tsuji; Y Sakai; M Kitahara; K Arai; T Yamashita; K Yokoyama; N Mukaida; K Matsushima; O Matsui; S Kaneko
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

5.  Dendritic cell infiltration and prognosis of human hepatocellular carcinoma.

Authors:  Xiao-Yan Cai; Qiang Gao; Shuang-Jian Qiu; Sheng-Long Ye; Zhi-Quan Wu; Jia Fan; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-19       Impact factor: 4.553

6.  Recruitment of dendritic cells in human liver with metastases.

Authors:  M Gulubova; I Manolova; G Cirovski; D Sivrev
Journal:  Clin Exp Metastasis       Date:  2008-06-27       Impact factor: 5.150

Review 7.  Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.

Authors:  Virginia Hernandez-Gea; Sara Toffanin; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2013-01-09       Impact factor: 22.682

Review 8.  Immunology of hepatocellular carcinoma.

Authors:  Meenakshi Sachdeva; Yogesh K Chawla; Sunil K Arora
Journal:  World J Hepatol       Date:  2015-08-18

9.  Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma.

Authors:  Ming Shi; Bing Zhang; Zi-Rong Tang; Zhou-Yun Lei; Hui-Fen Wang; Yong-Yi Feng; Zhen-Ping Fan; Dong-Ping Xu; Fu-Sheng Wang
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

10.  Autologous dendritic cell based adoptive immunotherapy of patients with colorectal cancer-A phase I-II study.

Authors:  János Hunyadi; Csilla András; Imre Szabó; János Szántó; Kornélia Szluha; Sándor Sipka; Péter Kovács; Attila Kiss; Gyula Szegedi; István Altorjay; Péter Sápy; Péter Antal-Szalmás; László Tóth; György Fazekas; Éva Rajnavölgyi
Journal:  Pathol Oncol Res       Date:  2013-10-28       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.